A bitter pill: Indian pharma industry, Trump’s tariff and a Congress that campaigned on cheaper care
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about tariffs and trade and pharma and health.
Directly affected
- No company is named in this report.
Indirectly affected
- XLI Industrial Select Sector SPDR+0.6% 30d
Industrial Select Sector SPDR: it holds companies hit by import costs and trade rules. Linked by “tariff” (tariffs and trade) in this story.
- XRT SPDR S&P Retail ETF
SPDR S&P Retail ETF: it holds companies hit by import costs and trade rules. Linked by “tariff” (tariffs and trade) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story.
- INDA iShares MSCI India ETF-2.2% 10d
iShares MSCI India ETF holds stocks listed in India, which this story is about (“indian”).
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- CAT Caterpillar-28.4% 30d
Caterpillar (construction machinery and equip): importers and exporters pay or lose sales when tariffs change. Linked by “tariff” (tariffs and trade) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLI | +0.05% | +1.29% | base | after close | after close | after close | after close |
| XRT | +1.88% | +1.40% | base | after close | after close | after close | after close |
| XLV | -0.28% | +0.04% | base | after close | after close | after close | after close |
| INDA | -0.06% | +0.23% | base | after close | after close | after close | after close |
| LLY | -2.25% | -0.49% | base | after close | after close | after close | after close |
| JNJ | -1.35% | -1.97% | base | after close | after close | after close | after close |
| CAT | -0.24% | +0.24% | base | after close | after close | after close | after close |
| PFE | +1.19% | +1.90% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
A bitter pill: Indian pharma industry, Trump’s tariff and a Congress that campaigned on cheaper care The Times of India
Source: The Times of India
This story
| Company | When | Move | Status |
|---|---|---|---|
| CAT | three days earlier | +0.24% | final price |
| CAT | five days earlier | -0.24% | final price |
| INDA | three days earlier | +0.23% | final price |
| INDA | five days earlier | -0.06% | final price |
| JNJ | three days earlier | -1.97% | final price |
| JNJ | five days earlier | -1.35% | final price |
| LLY | three days earlier | -0.49% | final price |
| LLY | five days earlier | -2.25% | final price |
| PFE | three days earlier | +1.90% | final price |
| PFE | five days earlier | +1.19% | final price |
| XLI | three days earlier | +1.29% | final price |
| XLI | five days earlier | +0.05% | final price |
| XLV | three days earlier | +0.04% | final price |
| XLV | five days earlier | -0.28% | final price |
| XRT | three days earlier | +1.40% | final price |
| XRT | five days earlier | +1.88% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 25 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 71 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 38 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 45 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lisa McClain bought Caterpillar (CAT) (held by a spouse), worth $1,001 - $15,000 on 28 Sep 2026. That is 47 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 71 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 85 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“A bitter pill: Indian pharma industry, Trump’s tariff and a Congress that campaigned on cheaper care” scores 12 out of 100. The score uses 1 sources.